Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
If Biotech manages to break out to new highs at some point this year, it would clear a significant resistance hurdle and open ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...
Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results